Article · Wikipedia archive · Last revised Jul 16, 2026

Spiradoline

Spiradoline (U-62066) is a drug which acts as a highly selective κ-opioid agonist. It has analgesic, diuretic, and antitussive effects, and produces subjective effects in animals similar to those of ketazocine and alazocine. The main effect in humans is sedation, along with analgesic and diuretic effects, but significant side effects such as dysphoria and hallucinations have stopped it from being used clinically.

Last revised
Jul 16, 2026
Read time
≈ 1 min
Length
272 w
Citations
6
Source
Wikipedia ↗
Spiradoline
Clinical data
Routes of
administration		N/A
ATC code
  • none
Identifiers
  • 2-(3,4-Dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl] acetamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H30Cl2N2O2
Molar mass425.39 g·mol−1
3D model (JSmol)
  • CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
  • InChI=1S/C22H30Cl2N2O2/c1-25(21(27)14-16-5-6-17(23)18(24)13-16)19-7-9-22(8-4-12-28-22)15-20(19)26-10-2-3-11-26/h5-6,13,19-20H,2-4,7-12,14-15H2,1H3/t19-,20-,22-/m0/s1 ☒N
  • Key:NYKCGQQJNVPOLU-ONTIZHBOSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Spiradoline (U-62066) is a drug which acts as a highly selective κ-opioid agonist.1 It has analgesic,2 diuretic,3 and antitussive effects,4 and produces subjective effects in animals similar to those of ketazocine and alazocine.5 The main effect in humans is sedation, along with analgesic and diuretic effects, but significant side effects such as dysphoria and hallucinations have stopped it from being used clinically.6

See also

See also

References

References

  1. Vonvoigtlander PF, Lewis RA (July 1988). "Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid". The Journal of Pharmacology and Experimental Therapeutics. 246 (1): 259–62. PMID 2839665.
  2. Kunihara M, Ohyama M, Nakano M, Hayashi S (1989). "Analgesic activity of spiradoline mesylate (U-62,066E), a kappa opioid agonist in mice". Life Sciences. 45 (13): 1191–8. doi:10.1016/0024-3205(89)90508-0. PMID 2796604.
  3. Yamada K, Imai M, Yoshida S (January 1989). "Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist". European Journal of Pharmacology. 160 (2): 229–37. doi:10.1016/0014-2999(89)90495-0. PMID 2547626.
  4. Kamei J, Tanihara H, Kasuya Y (October 1990). "Antitussive effects of two specific kappa-opioid agonists, U-50,488H and U-62,066E, in rats". European Journal of Pharmacology. 187 (2): 281–6. doi:10.1016/0014-2999(90)90014-w. PMID 2272363.
  5. Holtzman SG (July 2000). "Further characterization of the discriminative stimulus effects of spiradoline". Pharmacology, Biochemistry, and Behavior. 66 (3): 517–22. doi:10.1016/s0091-3057(00)00172-6. PMID 10899364. S2CID 27712517.
  6. Wadenberg ML (2003). "A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist". CNS Drug Reviews. 9 (2): 187–98. doi:10.1111/j.1527-3458.2003.tb00248.x. PMC 6741666. PMID 12847558.